oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2020-19-3-5-22oncotomsk-1483Research ArticleПЕРЕДОВАЯ СТАТЬЯLEADING ARTICLEВЛИЯНИЕ ПАНДЕМИИ COVID-19 НА ОНКОЛОГИЧЕСКУЮ ПРАКТИКУIMPACT OF THE COVID-19 PANDEMIC ON THE ONCOLOGICAL PRACTICEhttps://orcid.org/0000-0001-8784-8415КапринА. Д.KaprinA. D.

доктор медицинских наук, профессор, академик РАН, главный внештатный онколог Минздрава России; генеральный директор ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России;

директор Московского научно-исследовательского онкологического института им. П.А. Герцена,

Москва

MD, DSc, Professor, Member of the Russian Academy of Sciences, Chief Oncologist of Ministry of Health of Russia; General Director of National Medical Research Center of Radiology of Ministry of Health of Russia; Director of P.A. Hertsen Moscow Oncology Research Center,

3, 2nd Botkin Ave., 125284, Moscow

kaprin@mail.ruhttps://orcid.org/0000-0002-8509-4338ГамееваЕ. В.GameevaE. V.

кандидат медицинских наук, заместитель директора по лечебной работе,

Москва

MD, PhD, Deputy Director, 

3, 2nd Botkin Ave., 125284, Moscow

https://orcid.org/0000-0003-4117-0041ПоляковА. А.PolyakovA. A.

клинический ординатор,

Москва

MD, Clinical Resident, 

3, 2nd Botkin Ave., 125284, Moscow

https://orcid.org/0000-0003-0092-0459КорниецкаяА. Л.KornietskayaA. L.

кандидат медицинских наук, старший научный сотрудник отделения химиотерапии,

Москва

MD, PhD, Senior Researcher, Department of Chemotherapy,

3, 2nd Botkin Ave., 125284, Moscow

https://orcid.org/0000-0001-8378-4338РубцоваН. А.RubtsovaN. A.

доктор медицинских наук, заведующая отделом лучевой диагностики,

Москва

MD, DSc, Head of Radiology Department, 

3, 2nd Botkin Ave., 125284, Moscow

https://orcid.org/0000-0003-4927-5585ФеденкоА. А.FedenkoA. A.

доктор медицинских наук, руководитель отдела лекарственного лечения опухолей,

Москва

MD, DSc, Head of the Department of Drug Treatment of Tumors,

3, 2nd Botkin Ave., 125284, Moscow

fedenko@eesg.ruФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России; Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииРоссияNational Medical Research Center of Radiology of Ministry of Health of Russia; P.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of RussiaRussian FederationМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииРоссияP.A. Hertsen Moscow Oncology Research Center – branch of FSBI NMRRC of the Ministry of Health of RussiaRussian Federation202002072020193522Copyright © Каприн А.Д., Гамеева Е.В., Поляков А.А., Корниецкая А.Л., Рубцова Н.А., Феденко А.А., 20202020Каприн А.Д., Гамеева Е.В., Поляков А.А., Корниецкая А.Л., Рубцова Н.А., Феденко А.А.Kaprin A.D., Gameeva E.V., Polyakov A.A., Kornietskaya A.L., Rubtsova N.A., Fedenko A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1483

Проведен детальный, систематический обзор данных мировой литературы, включающий все аспекты, которые отражают влияние пандемии COVID-19 на онкологическую практику. Поиск информационных источников произведен в системах Pubmed, MedLine, Scopus, Web of Science, РИНЦ. Проанализированы данные ретроспективных и проспективных клинических исследований. В обзоре отражен опыт российских и зарубежных исследователей, представлены данные о влиянии COVID-19 на онкологических пациентов, смертности и прогнозе у онкологических больных, инфицированных COVID-19, возможностях лечения COVID-19, а также представлен нетипичный случай течения данной инфекции у онкобольного. На сегодняшний день выделены группы повышенного риска инфицирования новым коронавирусом, к ним относятся и пациенты c онкологическими заболеваниями. Несмотря на пандемию, лечение онкологических пациентов необходимо продолжать, так как наличие опухолевого процесса не допускает задержки в проведении терапии. Мировое онкологическое сообщество активно продолжает разрабатывать рекомендации по оптимальному ведению онкологических больных в условиях пандемии. Наиболее актуальные из них изложены в данной статье.

Detailed, systematic review of the world literature data, including all aspects that reflect the impact of the COVID-19 pandemic on the oncological practice was conducted. The information sources were taken from Pubmed, MedLine, Scopus, Web of Science, and RSCI systems. The data from retrospective and prospective clinical trials have been analyzed. This review presents current data on the impact of COVID-19 on cancer patients, mortality and prognosis of cancer patients infected with COVID-19, treatment options for COVID-19, as well as the case report of the cancer patient with rare atypical COVID-19 course of disease. To date, the groups of increased risk of being infected with a new coronavirus have been identified. These groups include cancer patients. Despite the pandemic, treatment of cancer patients must be continued, since the presence of a tumor process does not allow the therapy to be delayed. The world cancer community is actively continuing to develop recommendations for optimal management of cancer patients in the context of the pandemic. The most relevant of them are described in this article.

COVID-19SARS-CoV-2пандемияонкологиялекарственное лечение опухолейонкогематологиясолидные опухолиCOVID-19SARS-CoV-2pandemiconcologydrug treatment of tumorsoncohematologysolid tumorsReferencesGuan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S.; China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–20. doi: 10.1056/NEJMoa2002032.Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S.; China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–20. doi: 10.1056/NEJMoa2002032.Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., Chen C., Jin L., Yang R., Wang Q., Zhou S., Wang R., Liu H., Luo Y., Liu Y., Shao G., Li H., Tao Z., Yang Y., Deng Z., Liu B., Ma Z., Zhang Y., Shi G., Lam T.T.Y., Wu J.T., Gao G.F., Cowling B.J., Yang B., Leung G.M., Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26; 382(13): 1199–1207. doi: 10.1056/NEJMoa2001316.Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., Chen C., Jin L., Yang R., Wang Q., Zhou S., Wang R., Liu H., Luo Y., Liu Y., Shao G., Li H., Tao Z., Yang Y., Deng Z., Liu B., Ma Z., Zhang Y., Shi G., Lam T.T.Y., Wu J.T., Gao G.F., Cowling B.J., Yang B., Leung G.M., Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26; 382(13): 1199–1207. doi: 10.1056/NEJMoa2001316.Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15; 395(10223): 507–513. doi: 10.1016/S0140-6736(20)30211-7.Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15; 395(10223): 507–513. doi: 10.1016/S0140-6736(20)30211-7.Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., Diaz G., Cohn A., Fox L., Patel A., Gerber S.I., Kim L., Tong S., Lu X., Lindstrom S., Pallansch M.A., Weldon W.C., Biggs H.M., Uyeki T.M., Pillai S.K.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5; 382(10): 929–936. doi: 10.1056/NEJMoa2001191.Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H., Spitters C., Ericson K., Wilkerson S., Tural A., Diaz G., Cohn A., Fox L., Patel A., Gerber S.I., Kim L., Tong S., Lu X., Lindstrom S., Pallansch M.A., Weldon W.C., Biggs H.M., Uyeki T.M., Pillai S.K.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5; 382(10): 929–936. doi: 10.1056/NEJMoa2001191.Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5.Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395(10223): 497–506. doi: 10.1016/S0140-6736(20)30183-5.Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–9. doi: 10.1001/jama.2020.1585.Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–9. doi: 10.1001/jama.2020.1585.Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M., Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15; 395(10223): 514–523. doi: 10.1016/S0140-6736(20)30154-9.Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W., Tsoi H.W., Lo S.K., Chan K.H., Poon V.K., Chan W.M., Ip J.D., Cai J.P., Cheng V.C., Chen H., Hui C.K., Yuen K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15; 395(10223): 514–523. doi: 10.1016/S0140-6736(20)30154-9.Hoehl S., Rabenau H., Berger A., Kortenbusch M., Cinatl J., Bojkova D., Behrens P., Böddinghaus B., Götsch U., Naujoks F., Neumann P., Schork J., Tiarks-Jungk P., Walczok A., Eickmann M., Vehreschild M.J.G.T., Kann G., Wolf T., Gottschalk R., Ciesek S. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med. 2020 Mar 26; 382(13): 1278–1280. doi: 10.1056/NEJMc2001899.Hoehl S., Rabenau H., Berger A., Kortenbusch M., Cinatl J., Bojkova D., Behrens P., Böddinghaus B., Götsch U., Naujoks F., Neumann P., Schork J., Tiarks-Jungk P., Walczok A., Eickmann M., Vehreschild M.J.G.T., Kann G., Wolf T., Gottschalk R., Ciesek S. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med. 2020 Mar 26; 382(13): 1278–1280. doi: 10.1056/NEJMc2001899.Wang H., Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020 Apr; 21(4): e181. doi: 10.1016/S1470-2045(20)30149-2.Wang H., Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol. 2020 Apr; 21(4): e181. doi: 10.1016/S1470-2045(20)30149-2.You B., Ravaud A., Canivet A., Ganem G., Giraud P., Guimbaud R., Kaluzinski L., Krakowski I., Mayeur D., Grellety T., Lotz J.P. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol. 2020; 21(5): 619–21. doi: 10.1016/S1470-2045(20)30204-7.You B., Ravaud A., Canivet A., Ganem G., Giraud P., Guimbaud R., Kaluzinski L., Krakowski I., Mayeur D., Grellety T., Lotz J.P. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncol. 2020; 21(5): 619–21. doi: 10.1016/S1470-2045(20)30204-7.Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., Li S., He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar; 21(3): 335–337. doi: 10.1016/S1470-2045(20)30096-6.Liang W., Guan W., Chen R., Wang W., Li J., Xu K., Li C., Ai Q., Lu W., Liang H., Li S., He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar; 21(3): 335–337. doi: 10.1016/S1470-2045(20)30096-6.Burki T.K. Cancer care in the time of COVID-19. Lancet Oncol. 2020 May; 21(5): 628. doi: 10.1016/S1470-2045 (20)30201-1.Burki T.K. Cancer care in the time of COVID-19. Lancet Oncol. 2020 May; 21(5): 628. doi: 10.1016/S1470-2045 (20)30201-1.Burki T.K. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. 2020 May; 21(5): 629–630. doi: 10.1016/S1470-2045(20)30217-5.Burki T.K. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. 2020 May; 21(5): 629–630. doi: 10.1016/S1470-2045(20)30217-5.Wang Z., Wang J., He J. Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. JAMA Oncol. 2020; 6(5): 631632. doi: 10.1001/jamaoncol.2020.1198.Wang Z., Wang J., He J. Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China. JAMA Oncol. 2020; 6(5): 631632. doi: 10.1001/jamaoncol.2020.1198.ESMO. Cancer patient management during the COVID-19 pandemic [Internet]. URL: https://www.esmo.org/guidelines/cancer-patientmanagement-during-the-COVID-19-pandemic?hit=ehp&page=1 (cited 01.04.2020).ESMO. Cancer patient management during the COVID-19 pandemic [Internet]. URL: https://www.esmo.org/guidelines/cancer-patientmanagement-during-the-COVID-19-pandemic?hit=ehp&page=1 (cited 01.04.2020).Miyashita H., Mikami T., Chopra N., Yamada T., Chernyavsky S., Rizk D., Cruz C. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020 Apr 21: S09237534(20)39303-0. doi: 10.1016/j.annonc.2020.04.006.Miyashita H., Mikami T., Chopra N., Yamada T., Chernyavsky S., Rizk D., Cruz C. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020 Apr 21: S09237534(20)39303-0. doi: 10.1016/j.annonc.2020.04.006.Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) [Интернет]. URL: https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf (дата обращения: 01.04.2020).Temporary methodological recommendations: prevention, diagnosis and treatment of new coronaviral infection (COVID-19) [Internet]. URL: https://static1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf (cited 01.04.2020). (in Russian).I of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. URL: https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(COVID-19) (cited 01.04.2020).I of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. URL: https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(COVID-19) (cited 01.04.2020).Mehta V., Goel S., Kabarriti R., Cole D., Goldfinger M., Acuna-Villaorduna A., Pradhan K., Thota R., Reissman S., Sparano J.A., Gartrell B.A., Smith R.V., Ohri N., Garg M., Racine A.D., Kalnicki S., Perez-Soler R., Halmos B., Verma A. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 May 1: CD-20-0516. doi: 10.1158/2159-8290.CD-20-0516.Mehta V., Goel S., Kabarriti R., Cole D., Goldfinger M., Acuna-Villaorduna A., Pradhan K., Thota R., Reissman S., Sparano J.A., Gartrell B.A., Smith R.V., Ohri N., Garg M., Racine A.D., Kalnicki S., Perez-Soler R., Halmos B., Verma A. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020 May 1: CD-20-0516. doi: 10.1158/2159-8290.CD-20-0516.Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar; 30(3): 269–271. doi: 10.1038/s41422-020-0282-0.Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar; 30(3): 269–271. doi: 10.1038/s41422-020-0282-0.Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., Cooley L.A., Dean N.C., Fine M.J., Flanders S.A., Griffin M.R., Metersky M.L., Musher D.M., Restrepo M.I., Whitney C.G. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1; 200(7): e45e67. doi: 10.1164/rccm.201908-1581ST.Metlay J.P., Waterer G.W., Long A.C., Anzueto A., Brozek J., Crothers K., Cooley L.A., Dean N.C., Fine M.J., Flanders S.A., Griffin M.R., Metersky M.L., Musher D.M., Restrepo M.I., Whitney C.G. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1; 200(7): e45e67. doi: 10.1164/rccm.201908-1581ST.Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020; 395(10223): 473–475. doi: 10.1016/S0140-6736(20)30317-2.Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020; 395(10223): 473–475. doi: 10.1016/S0140-6736(20)30317-2.Поддубная И.В., Сычев Д.А. Особенности ведения онкологических пациентов во время пандемии коронавирусной инфекции COVID-19 [Интернет]. URL: https://rosoncoweb.ru/news/COVID-19/2020/04/07-2/module.pdf (дата обращения: 01.04.2020).Poddubnaya I.V., Sychev D.A. Features of managing of oncological patients during a pandemic of coronavirus infection COVID-19. [Internet]. URL: https://rosoncoweb.ru/news/COVID-19/2020/04/07-2/module.pdf (дата обращения: 01.04.2020). (in Russian).Hung I.F., Lung K.C., Tso E.Y., Liu R., Chung T.W., Chu M.Y., Ng Y.Y., Lo J ., Chan J., Tam A.R., Shum H.P., Chan V., Wu A.K., Sin K.M., Leung W.S., Law W.L., Lung D.C., Sin S., Yeung P., Yip C.C., Zhang R.R., Fung A.Y., Yan E.Y., Leung K.H., Ip J.D., Chu A.W., Chan W.M., Ng A.C., Lee R., Fung K., Yeung A., Wu T.C., Chan J.W., Yan W.W., Chan W.M., Chan J.F., Lie A.K., Tsang O.T., Cheng V.C., Que T.L., Lau C.S., Chan K.H., To K.K., Yuen K.Y. Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30; 395(10238): 1695–1704. doi: 10.1016/S0140-6736(20)31042-4.Hung I.F., Lung K.C., Tso E.Y., Liu R., Chung T.W., Chu M.Y., Ng Y.Y., Lo J ., Chan J., Tam A.R., Shum H.P., Chan V., Wu A.K., Sin K.M., Leung W.S., Law W.L., Lung D.C., Sin S., Yeung P., Yip C.C., Zhang R.R., Fung A.Y., Yan E.Y., Leung K.H., Ip J.D., Chu A.W., Chan W.M., Ng A.C., Lee R., Fung K., Yeung A., Wu T.C., Chan J.W., Yan W.W., Chan W.M., Chan J.F., Lie A.K., Tsang O.T., Cheng V.C., Que T.L., Lau C.S., Chan K.H., To K.K., Yuen K.Y. Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30; 395(10238): 1695–1704. doi: 10.1016/S0140-6736(20)31042-4.COVID-19: Elective Case Triage Guidelines for Surgical Care. American College of Surgeons. March 24, 2020. https://www.facs.org/COVID-19/clinical-guidance/elective-case/.COVID-19: Elective Case Triage Guidelines for Surgical Care. American College of Surgeons. March 24, 2020. https://www.facs.org/COVID-19/clinical-guidance/elective-case/.Mayor S. COVID-19: impact on cancer workforce and delivery of care. Lancet Oncol. 2020 May; 21(5): 633. doi: 10.1016/S1470- 2045(20)30240-0.Mayor S. COVID-19: impact on cancer workforce and delivery of care. Lancet Oncol. 2020 May; 21(5): 633. doi: 10.1016/S1470- 2045(20)30240-0.Simcock R., Thomas T.V., Estes C., Filippi A.R., Katz M.A., Pereira I.J., Saeed H. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020 Mar 24; 22: 55–68. doi: 10.1016/j.ctro.2020.03.009.Simcock R., Thomas T.V., Estes C., Filippi A.R., Katz M.A., Pereira I.J., Saeed H. COVID-19: Global radiation oncology’s targeted response for pandemic preparedness. Clin Transl Radiat Oncol. 2020 Mar 24; 22: 55–68. doi: 10.1016/j.ctro.2020.03.009.Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) у онкологических больных [Интернет]. URL: https://oncology-association.ru/files/pdf/2020/COVID.pdf (дата обращения: 01.04.2020).Prevention, diagnostics and treatment of new coronavirus infection (COVID-19) in oncologic patients [Internet]. URL: https://oncology-association.ru/files/pdf/2020/COVID.pdf (cited: 01.04.2020). (in Russian).ESMO management and treatment adapted recommendations in the COVID-19 era: primary brain tumours [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID19-pandemic/primary-brain-tumours-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: primary brain tumours [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID19-pandemic/primary-brain-tumours-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: diffuse large B-cell lymphoma, mantle cell lymphoma and aggressive T-cell lymphomas [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/haematological-malignancies-dlbcl-mcl-and-aggressive-t-cell-lymphomain-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: diffuse large B-cell lymphoma, mantle cell lymphoma and aggressive T-cell lymphomas [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/haematological-malignancies-dlbcl-mcl-and-aggressive-t-cell-lymphomain-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/haematological-malignancies-multiple-myeloma-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/haematological-malignancies-multiple-myeloma-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/breast-cancer-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/breast-cancer-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/gastrointestinal-cancers-colorectal-cancer-crc-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/gastrointestinal-cancers-colorectal-cancer-crc-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: renal cell cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/genitourinary-cancers-renal-cell-cancer-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: renal cell cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/genitourinary-cancers-renal-cell-cancer-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: prostate cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19- pandemic/genitourinary-cancers-prostate-cancer-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: prostate cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19- pandemic/genitourinary-cancers-prostate-cancer-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: epithelial ovarian cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/gynaecological-malignancies-epithelial-ovarian-cancer-in-theCOVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: epithelial ovarian cancer [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/gynaecological-malignancies-epithelial-ovarian-cancer-in-theCOVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: melanoma [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/melanoma-in-the-COVID-19-era (cited: 01.04.2020).ESMO management and treatment adapted recommendations in the COVID-19 era: melanoma [Internet]. URL: https://www.esmo.org/guidelines/cancer-patient-management-during-the-COVID-19-pandemic/melanoma-in-the-COVID-19-era (cited: 01.04.2020).Penel N., Bonvalot S., Minard V., Orbach D., Gouin F., Corradini N., Brahmi M., Marec-Bérard P., Briand S., Gaspar N., Llacer C., Carrère S., Dufresne A., Le Cesne A., Blay J.Y. French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak. Ann Oncol. 2020 Apr 9; 31(7): 965–966. doi: 10.1016/j.annonc.2020.03.308.Penel N., Bonvalot S., Minard V., Orbach D., Gouin F., Corradini N., Brahmi M., Marec-Bérard P., Briand S., Gaspar N., Llacer C., Carrère S., Dufresne A., Le Cesne A., Blay J.Y. French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak. Ann Oncol. 2020 Apr 9; 31(7): 965–966. doi: 10.1016/j.annonc.2020.03.308.Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020 Apr; 12(5): 269–273. doi: 10.2217/imt-2020-0067.Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020 Apr; 12(5): 269–273. doi: 10.2217/imt-2020-0067.Mei H., Dong X., Wang Y., Tang L., Hu Y. Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan. Lancet Oncol. 2020 May; 21(5): 634–636. doi: 10.1016/S1470- 2045(20)30238-2.Mei H., Dong X., Wang Y., Tang L., Hu Y. Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan. Lancet Oncol. 2020 May; 21(5): 634–636. doi: 10.1016/S1470- 2045(20)30238-2.Главный внештатный онколог Минздрава: рак не уходит на карантин [Интернет]. URL: https://tass.ru/interviews/8391689 (дата обращения: 01.04.2020).Chief freelance oncologist of the Ministry of Health: cancer does not go to quarantine [Internet]. URL: https://tass.ru/interviews/8391689 (cited 01.04.2020). (in Russian).Геращенко Я.Л. Обзор клинических рекомендаций по ведению пациентов с подтвержденной коронавирусной болезнью (COVID-19) выпущенных Американским национальным центром иммунизации и респираторных заболеваний (NCIRD). Русский медицинский журнал [Интернет]. URL: https://www.rmj.ru/articles/infektsiya/obzorklinicheskikh-rekomendatsiy-po-vedeniyu-patsientov-s-podtverzhdennoykoronavirusnoy-boleznyu-COVID-19-vypushchennykh-amerikanskimnatsionalnym-tsentrom-immunizatsii-i-respiratornykh-zabolevaniy-ncird/ (дата обращения: 01.04.2020).Gerashchenko Ya.L. Review of clinical guidelines for the management of patients with confirmed coronavirus disease (COVID-19) issued by the American national center for immunization and respiratory diseases (NCIRD). Russian Medical Journal [Internet]. URL: https://www.rmj.ru/articles/infektsiya/obzor-klinicheskikh-rekomendatsiy-povedeniyu-patsientov-s-podtverzhdennoy-koronavirusnoy-boleznyu-COVID19-vypushchennykh-amerikanskim-natsionalnym-tsentrom-immunizatsii-irespiratornykh-zabolevaniy-ncird/ (cited 01.04.2020). (in Russian).

The authors declare that there are no conflicts of interest present.